These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 19694499)

  • 1. Enhancing mTOR-targeted cancer therapy.
    Wang X; Sun SY
    Expert Opin Ther Targets; 2009 Oct; 13(10):1193-203. PubMed ID: 19694499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
    Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun SY
    Cancer Biol Ther; 2008 Dec; 7(12):1952-8. PubMed ID: 18981735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR kinase inhibitors as potential cancer therapeutic drugs.
    Sun SY
    Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the mTOR signaling network for cancer therapy.
    Meric-Bernstam F; Gonzalez-Angulo AM
    J Clin Oncol; 2009 May; 27(13):2278-87. PubMed ID: 19332717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward rapamycin analog (rapalog)-based precision cancer therapy.
    Meng LH; Zheng XF
    Acta Pharmacol Sin; 2015 Oct; 36(10):1163-9. PubMed ID: 26299952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic alterations on mTOR-targeted cancer therapy.
    Sun SY
    Chin J Cancer; 2013 May; 32(5):270-4. PubMed ID: 23489586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance to rapalogs in gliomas by combinatory therapies.
    Grzmil M; Hemmings BA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1371-80. PubMed ID: 23395884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current development of the second generation of mTOR inhibitors as anticancer agents.
    Zhou HY; Huang SL
    Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin as a therapeutic target in oncology.
    Abraham RT; Eng CH
    Expert Opin Ther Targets; 2008 Feb; 12(2):209-22. PubMed ID: 18208369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Adv Exp Med Biol; 2006; 587():309-27. PubMed ID: 17163174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR signaling and drug development in cancer.
    Dancey J
    Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.